Related Experiment Videos
Prospective, longitudinal oncology registries enabling advanced real-world evidence: the iOMEDICO experience
Background:
Randomized controlled trials (RCTs) remain the gold standard for evidence on treatment efficacy but face limitations: restrictive eligibility criteria exclude real-world populations, head-to-head comparisons between approved regimens are rare, and absolute effectiveness in unselected cohorts often differs from trial results. High-quality cancer registries address these gaps by documenting treatment reality and quantifying effectiveness outside trial settings. We describe how the breadth and depth of prospective, longitudinal oncology registry data enable advanced research complementing RCTs.
Materials And Methods:
The iOMEDICO oncologist and hematologist network currently operates nine prospective, multicenter registry platforms across major cancer types in Germany. The registries employ regulatory-grade electronic data capture with audit trails, continuous data management, and consecutive patient enrollment. Beyond demographics and clinical variables, platforms systematically collect comorbidities, comprehensive biomarker data, complete treatment pathways, and patient-reported outcomes (PROs).
Results:
More than 55 000 patients have been documented so far across >400 sites representing diverse care settings. Our registry data enable patient-centered research in diverse applications: (i) characterizations of patient populations, treatment patterns, and outcomes to evaluate the current standards of care, identify unmet needs, and follow developments over time; (ii) predictive and prognostic model developments; (iii) comparative effectiveness research such as target trial emulation for head-to-head treatment comparisons; (iv) translational research into biomarker prevalence; and (v) evaluation of PROs.
Conclusion:
Well-designed prospective, longitudinal registries collecting broad and deep real-world data complement RCTs, inform Health Technology Assessments, and fill knowledge gaps by creating treatment transparency, addressing evidence gaps, and providing realistic outcome expectations for the heterogeneous populations in routine care.
Insights
High-quality cancer registries offer valuable real-world data to complement randomized controlled trials (RCTs). These prospective, longitudinal oncology registries capture comprehensive patient information, enhancing treatment research and providing realistic outcome expectations for diverse patient populations.
Area of Science:
- Oncology
- Real-World Evidence
- Clinical Research
Background:
- Randomized controlled trials (RCTs) are limited by strict eligibility criteria, rare head-to-head comparisons, and differing real-world effectiveness.
- High-quality cancer registries capture treatment reality and effectiveness outside trial settings.
- Prospective, longitudinal oncology registry data offer advanced research capabilities complementing RCTs.
Purpose of the Study:
- To describe how prospective, longitudinal oncology registry data can be leveraged for advanced research.
- To highlight the capabilities of the iOMEDICO registry network in Germany.
- To demonstrate the value of real-world data in complementing RCTs.
Main Methods:
- Operation of nine prospective, multicenter registry platforms across major cancer types in Germany by the iOMEDICO network.
- Use of regulatory-grade electronic data capture with audit trails and continuous data management.
- Systematic collection of demographics, clinical variables, comorbidities, biomarkers, treatment pathways, and patient-reported outcomes (PROs).
Main Results:
- Documentation of over 55,000 patients across more than 400 diverse care sites.
- Registry data enable patient-centered research, including population characterization, predictive modeling, and comparative effectiveness research.
- Applications include evaluating standards of care, identifying unmet needs, translational research, and PRO evaluation.
Conclusions:
- Well-designed prospective, longitudinal registries provide broad and deep real-world data.
- These registries complement RCTs, inform Health Technology Assessments, and fill knowledge gaps.
- They enhance treatment transparency, address evidence gaps, and set realistic outcome expectations for heterogeneous patient populations.
Related Concept Videos
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Longitudinal Research
Treatment Resistent Cancers
Cancer Survival Analysis
Treatment Resistant Cancers